Screener
Rigel Pharmaceuticals RIGL Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,486 | $7,191 |
| Accrued compensation | 6,009 | 11,914 |
| Accrued research and development | 5,742 | 5,524 |
| Acquisition-related liabilities | 5,000 | 5,000 |
| Revenue reserves and refund liability | 28,080 | 27,716 |
| Loans payable, net, current portion | 29,865 | 29,812 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's accrued expenses?
- Rigel Pharmaceuticals (RIGL) reported accrued expenses of $6.01M in Q1 2026.
- How has Rigel Pharmaceuticals's accrued expenses changed year-over-year?
- Rigel Pharmaceuticals's accrued expenses decreased by 0.2% year-over-year, from $6.02M to $6.01M.
- What is the long-term trend for Rigel Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's accrued expenses has grown at a 4.4% compound annual growth rate (CAGR), from $9.59M to $11.91M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Rigel Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude